ACE and COVID-19: This coagulation dysfunction, along with the hypertension status that was observed in 58.8% of COVID-19 patients who were taking ACE inhibitors as treatment for their hypertension, could support the other findings regarding the possible association between COVID-19 infection and ICH development [14].